Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Breccia

Showing results (31-40 of 427) with videos related to

Pageof 43
Sort By:
Expert Opinion on Biological Therapy|December 15, 2010
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacyMassimo Breccia, Francesco Lo-Coco
Expert Opinion on Pharmacotherapy|April 4, 2012
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent diseaseMassimo Breccia, Francesco Lo-Coco
Rare Cancers and Therapy|May 17, 2016
Molecular Monitoring as a Path to Cure Acute Promyelocytic LeukemiaFederico De Angelis, Massimo Breccia
Thrombosis Research|May 28, 2014
Thrombo-hemorrhagic deaths in acute promyelocytic leukemiaMassimo Breccia, Francesco Lo Coco
Expert Review of Hematology|December 17, 2016
How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changesFulvio Massaro, Matteo Molica, Massimo Breccia
British Journal of Haematology|November 27, 2024
Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategiesAlessandro Costa, Emilia Scalzulli, Massimo Breccia
Mediterranean Journal of Hematology and Infectious Diseases|September 21, 2020
Prognostic Significance of Transcript-Type <i>BCR - ABL1</i> in Chronic Myeloid LeukemiaMatteo Molica, Elisabetta Abruzzese, Massimo Breccia
Current Cancer Drug Targets|October 4, 2017
Ponatinib: A Review of Efficacy and SafetyFulvio Massaro, Matteo Molica, Massimo Breccia
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 18, 2013
Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML)Elisabetta Abruzzese, Massimo Breccia, Roberto Latagliata
Expert Opinion on Pharmacotherapy|December 1, 2016
Second line small molecule therapy options for treating chronic myeloid leukemiaMatteo Molica, Fulvio Massaro, Massimo Breccia
Pageof 43

Showing results (31-40 of 427) with videos related to

Sort By:
Pageof 43
Expert Opinion on Biological Therapy|December 15, 2010
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacyMassimo Breccia, Francesco Lo-Coco
Expert Opinion on Pharmacotherapy|April 4, 2012
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent diseaseMassimo Breccia, Francesco Lo-Coco
Rare Cancers and Therapy|May 17, 2016
Molecular Monitoring as a Path to Cure Acute Promyelocytic LeukemiaFederico De Angelis, Massimo Breccia
Thrombosis Research|May 28, 2014
Thrombo-hemorrhagic deaths in acute promyelocytic leukemiaMassimo Breccia, Francesco Lo Coco
Expert Review of Hematology|December 17, 2016
How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changesFulvio Massaro, Matteo Molica, Massimo Breccia
British Journal of Haematology|November 27, 2024
Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategiesAlessandro Costa, Emilia Scalzulli, Massimo Breccia
Mediterranean Journal of Hematology and Infectious Diseases|September 21, 2020
Prognostic Significance of Transcript-Type <i>BCR - ABL1</i> in Chronic Myeloid LeukemiaMatteo Molica, Elisabetta Abruzzese, Massimo Breccia
Current Cancer Drug Targets|October 4, 2017
Ponatinib: A Review of Efficacy and SafetyFulvio Massaro, Matteo Molica, Massimo Breccia
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 18, 2013
Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML)Elisabetta Abruzzese, Massimo Breccia, Roberto Latagliata
Expert Opinion on Pharmacotherapy|December 1, 2016
Second line small molecule therapy options for treating chronic myeloid leukemiaMatteo Molica, Fulvio Massaro, Massimo Breccia
Pageof 43